Cargando…
Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
BACKGROUND AND PURPOSE: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti‐apoptotic action, with potential neuroprotective a...
Autores principales: | Elia, A. E., Lalli, S., Monsurrò, M. R., Sagnelli, A., Taiello, A. C., Reggiori, B., La Bella, V., Tedeschi, G., Albanese, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024041/ https://www.ncbi.nlm.nih.gov/pubmed/25664595 http://dx.doi.org/10.1111/ene.12664 |
Ejemplares similares
-
Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol
por: Albanese, Alberto, et al.
Publicado: (2022) -
Amyotrophic Lateral Sclerosis and Multiple Sclerosis Overlap: A Case Report
por: Trojsi, Francesca, et al.
Publicado: (2012) -
Exposure to Environmental Toxicants and Pathogenesis of Amyotrophic Lateral Sclerosis: State of the Art and Research Perspectives
por: Trojsi, Francesca, et al.
Publicado: (2013) -
Effect of tauroursodeoxycholic acid on survival and safety in amyotrophic lateral sclerosis: a retrospective population-based cohort study
por: Zucchi, Elisabetta, et al.
Publicado: (2023) -
Widespread Structural and Functional Connectivity Changes in Amyotrophic Lateral Sclerosis: Insights from Advanced Neuroimaging Research
por: Trojsi, Francesca, et al.
Publicado: (2012)